146 related articles for article (PubMed ID: 37996643)
1. Characterizing the Immune Environment in Peritoneal Carcinomatosis: Insights for Novel Immunotherapy Strategies.
Wagner PL; Knotts CM; Donneberg VS; Dadgar N; Pico CC; Xiao K; Zaidi A; Schiffman SC; Allen CJ; Donnenberg AD; Bartlett DL
Ann Surg Oncol; 2024 Mar; 31(3):2069-2077. PubMed ID: 37996643
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal cytokine level in patients with peritoneal surface malignancies. A study of the RENAPE (French Network for Rare Peritoneal Malignancies).
Vlaeminck-Guillem V; Bienvenu J; Isaac S; Grangier B; Golfier F; Passot G; Bakrin N; Rodriguez-Lafrasse C; Gilly FN; Glehen O
Ann Surg Oncol; 2013 Aug; 20(8):2655-62. PubMed ID: 23519518
[TBL] [Abstract][Full Text] [Related]
3. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer.
Yasumoto K; Koizumi K; Kawashima A; Saitoh Y; Arita Y; Shinohara K; Minami T; Nakayama T; Sakurai H; Takahashi Y; Yoshie O; Saiki I
Cancer Res; 2006 Feb; 66(4):2181-7. PubMed ID: 16489019
[TBL] [Abstract][Full Text] [Related]
4. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
[TBL] [Abstract][Full Text] [Related]
5. Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis.
Dadgar N; Sherry C; Zimmerman J; Park H; Lewis C; Donnenberg A; Zaidi AH; Fan Y; Xiao K; Bartlett D; Donnenberg V; Wagner PL
J Transl Med; 2024 Apr; 22(1):402. PubMed ID: 38689325
[TBL] [Abstract][Full Text] [Related]
6. Ascitic fluid analysis in malignancy-related ascites.
Runyon BA; Hoefs JC; Morgan TR
Hepatology; 1988; 8(5):1104-9. PubMed ID: 3417231
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal carcinomatosis with intraperitoneal immunotherapy: current treatment options and perspectives.
Wei GX; Du Y; Zhou YW; Li LJ; Qiu M
Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):851-861. PubMed ID: 36107723
[TBL] [Abstract][Full Text] [Related]
8. Ascitic fluid analysis in peritoneal carcinomatosis: comparison of various biochemical tests with ascitic cirrhotics.
Lu CW; Wang SS; Lee SD; Tsai YT; Lee FY; Shiesh SC; Wu SL; Lu RH; Lo KJ
Zhonghua Yi Xue Za Zhi (Taipei); 1991 May; 47(5):350-6. PubMed ID: 1649678
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Value of Carcinoembryonic Antigen in Ascites for Colorectal Cancer with Peritoneal Carcinomatosis.
Song SE; Choi P; Kim JH; Jung K; Kim SE; Moon W; Park MI; Park SJ
Korean J Gastroenterol; 2018 Jun; 71(6):332-337. PubMed ID: 29943560
[TBL] [Abstract][Full Text] [Related]
10. Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma.
Na K; Lee JY; Sung JY; Kim GM; Koo JS; Kim HS
Virchows Arch; 2018 Aug; 473(2):165-175. PubMed ID: 29926183
[TBL] [Abstract][Full Text] [Related]
11. Cytokines in peritoneal fluid of ovarian neoplasms.
de Lima CA; Silva Rodrigues IS; Martins-Filho A; Côbo Micheli D; Martins Tavares-Murta B; Candido Murta EF; Simões Nomelini R
J Obstet Gynaecol; 2020 Apr; 40(3):401-405. PubMed ID: 31476946
[TBL] [Abstract][Full Text] [Related]
12. Serum and peritoneal fluid concentrations of soluble human leukocyte antigen, tumor necrosis factor alpha and interleukin 10 in patients with selected ovarian pathologies.
Sipak-Szmigiel O; Włodarski P; Ronin-Walknowska E; Niedzielski A; Karakiewicz B; Słuczanowska-Głąbowska S; Laszczyńska M; Malinowski W
J Ovarian Res; 2017 Apr; 10(1):25. PubMed ID: 28376925
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer.
Lee YS; Lee WS; Kim CW; Lee SJ; Yang H; Kong SJ; Ning J; Yang KM; Kang B; Kim WR; Chon HJ; Kim C
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199510
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal CMP-001: A Novel Immunotherapy for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer.
Miller AM; Lemke-Miltner CD; Blackwell S; Tomanek-Chalkley A; Gibson-Corely KN; Coleman KL; Weiner GJ; Chan CHF
Ann Surg Oncol; 2021 Feb; 28(2):1187-1197. PubMed ID: 32409965
[TBL] [Abstract][Full Text] [Related]
15. Utility of ascitic tumor markers and adenosine deaminase for differential diagnosis of tuberculous peritonitis and peritoneal carcinomatosis.
Du L; Wei X; Xiao Z; Wang H; Song Y
BMC Gastroenterol; 2022 Sep; 22(1):423. PubMed ID: 36115972
[TBL] [Abstract][Full Text] [Related]
16. Targeting carcinoma-associated mesothelial cells with antibody-drug conjugates in ovarian carcinomatosis.
Pascual-Antón L; Sandoval P; González-Mateo GT; Kopytina V; Tomero-Sanz H; Arriero-País EM; Jiménez-Heffernan JA; Fabre M; Egaña I; Ferrer C; Simón L; González-Cortijo L; Sainz de la Cuesta R; López-Cabrera M
J Pathol; 2023 Oct; 261(2):238-251. PubMed ID: 37555348
[TBL] [Abstract][Full Text] [Related]
17. Dual blockade of MET and VEGFR2 signaling pathways as a potential therapeutic maneuver for peritoneal carcinomatosis in scirrhous gastric cancer.
Kasai S; Kuwayama N; Motoo Y; Kawashima A; Matsumoto K; Yano S; Matsushima K; Yasumoto K
Biochem Biophys Res Commun; 2022 Apr; 600():80-86. PubMed ID: 35196631
[TBL] [Abstract][Full Text] [Related]
18. Is ascites CEA a risk factor for peritoneal carcinomatosis in colorectal cancer?: a long-term follow-up study.
Kim BC; Bae JH; Park SM; Won DY; Lee IK
Int J Colorectal Dis; 2020 Jan; 35(1):147-155. PubMed ID: 31802190
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiology of elevated ascites fluid cholesterol in malignant ascites. Increased ascites to serum relation of proteins and lipoproteins in patients with peritoneal carcinomatosis as compared to patients with cirrhosis of the liver.
Jüngst D; Xie Y; Gerbes AL
J Hepatol; 1992 Mar; 14(2-3):244-8. PubMed ID: 1500688
[TBL] [Abstract][Full Text] [Related]
20. Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis.
Lauer UM; Schell M; Beil J; Berchtold S; Koppenhöfer U; Glatzle J; Königsrainer A; Möhle R; Nann D; Fend F; Pfannenberg C; Bitzer M; Malek NP
Clin Cancer Res; 2018 Sep; 24(18):4388-4398. PubMed ID: 29773661
[No Abstract] [Full Text] [Related]
[Next] [New Search]
